Payment overview · 2025
General Payments
$148.44
9 reported records · 7 companies
Healthcare provider profile · identity verified
Mobolaji B Suleiman, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · KANKAKEE, IL · NPI 1184764086
Verified facts
What the public records show
CMS Open Payments records show Mobolaji B Suleiman, MD received $148.44 in general payments during 2025 across 9 reported records.
GlaxoSmithKline, LLC. accounted for 23.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.56 | 23.3% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $27.83 | 18.8% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.91 | 14.8% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $18.47 | 12.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.57 | 11.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.03 | 10.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.07 | 9.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $148.44 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $34.56 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $27.83 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $21.91 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $18.47 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.57 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.03 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 86 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
86 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1109 | 288 |
| Gabapentin | Gabapentin | 704 | 149 |
| Levothyroxine Sodium | Levothyroxine Sodium | 623 | 146 |
| Pantoprazole Sodium | Pantoprazole Sodium | 617 | 162 |
| Amlodipine Besylate | Amlodipine Besylate | 577 | 137 |
| Losartan Potassium | Losartan Potassium | 504 | 130 |
| Omeprazole | Omeprazole | 339 | 89 |
| Escitalopram Oxalate | Escitalopram Oxalate | 331 | 66 |
| Furosemide | Furosemide | 327 | 98 |
| Potassium Chloride | Potassium Chloride | 325 | 81 |
| Lisinopril | Lisinopril | 294 | 89 |
| Memantine Hcl | Memantine Hcl | 293 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 284 | 87 |
| Eliquis | Apixaban | 244 | 41 |
| Donepezil Hcl | Donepezil Hcl | 243 | 67 |
| Metoprolol Tartrate | Metoprolol Tartrate | 219 | 49 |
| Metformin Hcl | Metformin Hcl | 216 | 64 |
| Fluticasone Propionate | Fluticasone Propionate | 212 | 99 |
| Carvedilol | Carvedilol | 211 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 206 | 53 |
| Sertraline Hcl | Sertraline Hcl | 203 | 49 |
| Allopurinol | Allopurinol | 201 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 200 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 184 | 57 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 182 | 42 |
| Montelukast Sodium | Montelukast Sodium | 163 | 39 |
| Jardiance | Empagliflozin | 162 | 37 |
| Meloxicam | Meloxicam | 159 | 54 |
| Mirtazapine | Mirtazapine | 146 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 143 | 36 |
| Simvastatin | Simvastatin | 138 | 41 |
| Ozempic | Semaglutide | 136 | 24 |
| Tramadol Hcl | Tramadol Hcl | 128 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 123 | 52 |
| Spironolactone | Spironolactone | 123 | 28 |
| Trazodone Hcl | Trazodone Hcl | 116 | 23 |
| Metformin Hcl Er | Metformin Hcl | 112 | 31 |
| Lorazepam | Lorazepam | 98 | 22 |
| Alprazolam | Alprazolam | 88 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 88 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 86 | 13 |
| Divalproex Sodium | Divalproex Sodium | 82 | 18 |
| Warfarin Sodium | Warfarin Sodium | 77 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 73 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 70 | 18 |
| Torsemide | Torsemide | 65 | 14 |
| Celecoxib | Celecoxib | 62 | 17 |
| Ipratropium Bromide | Ipratropium Bromide | 61 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 60 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 14 |
| Xarelto | Rivaroxaban | 56 | 13 |
| Prednisone | Prednisone | 54 | 31 |
| Paroxetine Hcl | Paroxetine Hcl | 53 | 11 |
| Ezetimibe | Ezetimibe | 52 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 51 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 49 | 13 |
| Buspirone Hcl | Buspirone Hcl | 49 | 12 |
| Clonidine Hcl | Clonidine Hcl | 47 | 14 |
| Bupropion Xl | Bupropion Hcl | 46 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 21 |
| Myrbetriq | Mirabegron | 45 | 14 |
| Clonazepam | Clonazepam | 44 | suppressed |
| Glipizide | Glipizide | 44 | 15 |
| Methylprednisolone | Methylprednisolone | 43 | 36 |
| Bumetanide | Bumetanide | 42 | suppressed |
| Latanoprost | Latanoprost | 40 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 34 |
| Glipizide Er | Glipizide | 39 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 39 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 33 |
| Azithromycin | Azithromycin | 38 | 31 |
| Cephalexin | Cephalexin | 38 | 34 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | 12 |
| Meclizine Hcl | Meclizine Hcl | 38 | 18 |
| Famotidine | Famotidine | 36 | 11 |
| Levetiracetam | Levetiracetam | 36 | suppressed |
| Hydrocortisone | Hydrocortisone | 35 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 35 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 34 | 13 |
| Finasteride | Finasteride | 34 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | suppressed |
| Synthroid | Levothyroxine Sodium | 34 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 34 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 32 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Ondansetron Odt | Ondansetron | 32 | 19 |
| Sucralfate | Sucralfate | 32 | 14 |
| Trulicity | Dulaglutide | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Entresto | Sacubitril/Valsartan | 31 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Irbesartan | Irbesartan | 28 | suppressed |
| Tradjenta | Linagliptin | 28 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 21 |
| Diazepam | Diazepam | 25 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Klor-Con M20 | Potassium Chloride | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Clozapine | Clozapine | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Calcitriol | Calcitriol | 19 | suppressed |
| Cefdinir | Cefdinir | 19 | 16 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Methimazole | Methimazole | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Sotalol | Sotalol Hcl | 19 | suppressed |
| Brilinta | Ticagrelor | 18 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 12 |
| Pregabalin | Pregabalin | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Budesonide | Budesonide | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Rifampin | Rifampin | 13 | suppressed |
| Abilify Maintena | Aripiprazole | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Drizalma Sprinkle | Duloxetine Hcl | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $148.44 · 9 records | GlaxoSmithKline, LLC. | EVENITY, FARXIGA, GVOKE HYPOPEN, TRELEGY ELLIPTA, VOQUEZNA, XIFAXAN, YUPELRI | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error